Related Experiment Videos

Thrombolysis of occluded femoropopliteal grafts

Insights

Urokinase thrombolysis demonstrated superior outcomes (77% success) and fewer complications (23%) compared to streptokinase for occluded femoropopliteal grafts. This effective treatment offers advantages over thrombectomy, preserving graft integrity and improving distal circulation.

Area of Science:

  • Vascular Surgery
  • Interventional Radiology
  • Thrombolytic Therapy

Background:

  • Femoropopliteal graft occlusion is a significant clinical challenge.
  • Thrombectomy has limitations in treating occluded grafts.

Purpose of the Study:

  • To compare the efficacy and safety of streptokinase versus urokinase for thrombolytic therapy in occluded femoropopliteal grafts.
  • To evaluate the long-term patency and outcomes of thrombolytic treatment.

Main Methods:

  • A series of 44 patients with occluded femoropopliteal grafts were treated.
  • 22 patients received streptokinase, and 22 received urokinase via indwelling arterial catheter.
  • Heparin infusion was used concomitantly to prevent recurrent thrombosis.

Main Results:

  • Urokinase achieved a higher success rate (77%) with fewer complications (23%) compared to streptokinase (41% success, 50% complications).
  • 11 out of 26 successfully treated grafts remained patent at an average of 12 months.
  • Surgical thrombectomy was ineffective in revascularizing limbs in failure cases.

Conclusions:

  • Urokinase is a more effective and safer thrombolytic agent for femoropopliteal graft occlusion than streptokinase.
  • Thrombolysis offers advantages over thrombectomy, including less graft trauma and improved distal runoff.
  • Despite time and cost, thrombolysis provides significant benefits for selected patients with occluded femoropopliteal grafts.

Related Concept Videos